FebriDx provides clinicians with a 10-minute assessment of the body’s immune response to an acute respiratory infection (ARI) directly from a fingerstick blood sample.
New Clinical Trial Demonstrates that FebriDx Can Accurately Identify Clinically Significant Bacterial Infections and May Support Outpatient Antibiotic Stewardship
5/21/18: “The overuse of antibiotics is a significant and growing problem,” said Robert Sambursky, MD, RPS Diagnostics’ President and Chief Executive Officer. “FebriDx provides clinicians a tool for rapidly measuring an immune response. This information facilitates clinical decision making and reduces unnecessary antibiotic prescribing.”